Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
\- Women who had been receiving once-weekly alendronate or risedronate for treatment or prevention of post-menopausal osteoporosis for greater than or equal to (\>=) 3 months
You may not be if
Inability to stand or sit upright for \>=60 minutes
Hypersensitivity to bisphosphonates
Inability to swallow a tablet whole
Malignant disease diagnosed within previous 10 years (except resected basal cell cancer).
Clareo Health | A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
